Grounded in research.

In a real-world analysis of 76,138 people who used Nerva, those who reported more severe anxiety and depression symptoms at the beginning of the program were just as likely to be able to manage their abdominal pain as those with none. The proportion who managed their pain was the same across every severity group, including the most severe.

“Over half of completers in every severity category, including those with severe psychological symptoms, achieved clinically meaningful pain reduction.”

“These data suggest that baseline psychological comorbidity should not deter clinicians from recommending digital GDH for IBS.”

In a real-world analysis of 26,008 people who used Nerva, those who identified food as their primary symptom trigger did as well as those who identified stress as their primary trigger. Both groups used the program at the same rate, with no significant difference in adherence.

“These data do not support the assumption that brain-gut behavioural therapy is less suitable for users who identify food rather than stress as their predominant trigger; food-only and stress-only users showed similar engagement and symptom improvement outcomes.”

In a real-world retrospective analysis of the Nerva program, older adults (65+) adhered better to the program and a higher proportion were able to manage their abdominal pain compared to younger users.

“Older adults with IBS demonstrated higher engagement and improved abdominal pain outcomes with digital GDH compared with younger users.”

“These data suggest that digital GDH is feasible and associated with meaningful engagement across the adult age spectrum, including older populations.”

Across 22,821 participants (5,438 men / 17,383 women), men were less likely to be clinician-referred and slightly less likely to initiate the program. Women showed higher retention at every checkpoint, Day 7 (81.9% vs 78.5%), Day 14 (75.9% vs 71.8%), Day 30 (65.9% vs 59.3%), with men demonstrating a steeper early decline beginning in the first week. But 74% of men self-referred, indicating substantial interest in BGBT.

Because therapeutic benefits typically emerge later in the course, early attrition among men may be limiting their opportunity for meaningful clinical improvement. And it points to the need for targeted strategies to strengthen early adherence for men.

Analysis of 33,061 Nerva users. Diaphragmatic breathing (DB) combined with hypnotherapy showed a consistent dose-response in users with moderate and severe baseline IBS-VAS, but not mild. Users completing 4+ DB sessions saw the greatest IBS-VAS reductions. Importantly, DB provided a stable additive benefit across all hypnotherapy dose bands, suggesting it contributes independent value regardless of hypnotherapy engagement level.

The greatest improvements came in users completing 4+ DB sessions and 41–45 hypnotherapy sessions over the 6-week program. These findings support the structured use of the diaphragmatic breathing, and it's the first published evidence that our DB content is driving measurable incremental improvement.

Mount Sinai researchers found that IBS users with concurrent upper GI symptoms saw comparable or greater IBS improvement than IBS-only users, despite more severe baseline symptoms. Their UGI symptoms also improved, suggesting gut-brain therapy can address both conditions.

Our 6-year real-world analysis of 194,879 Nerva users, one of the largest gut-brain therapy cohorts, shows adherence and outcomes climbing as we iterate. 45% of adherent users reached clinically meaningful pain reduction (vs 34% non-adherent). Nerva isn't static. It keeps getting better.

App-delivered gut-directed hypnotherapy improves overall and individual gastrointestinal symptoms. Users who complete the program report greater improvement in psychological outcomes. Healthcare practitioner referral is a positive predictor of program completion, but it does not alter rates of efficacy.

Mobile app-delivered gut-directed hypnotherapy significantly improved overall and specific symptoms of IBS similar to rates seen in face-to-face trials. IBS patients who respond poorly to medications may respond better. Mobile app-delivered gut-directed hypnotherapy may provide a cost-effective and accessible alternative to otherwise inaccessible therapy.

In a retrospective audit of pediatric users, the majority reported improved gastrointestinal symptom management and psychological outcomes.

These findings support the use of Nerva in paediatric populations and suggest the need for further research.

In a retrospective audit, the Nerva app's gut-directed hypnotherapy program significantly reduced abdominal pain and gastrointestinal symptoms in 64% of IBS patients who completed the program without apparent adverse effects.

Durable effects of gut-directed hypnotherapy are similar to those of the low FODMAP diet for relief of gastrointestinal symptoms. Hypnotherapy has superior efficacy to diet on psychological indices.

In a retrospective analysis of nearly 15,000 Nerva app users, adherence was comparable to or exceeded that of similar real-world digital health interventions, with older users (50+) significantly more likely to complete the full six-week program.

In a study of over 17,000 Nerva users, completing the app's gut-directed hypnotherapy program was associated with an approximate halving of IBS management costs, from $1,259 to $502 over six months, alongside significant long-term improvements in work absenteeism, presenteeism, and overall productivity.